Confronting Complexity: A Case Challenge in Short Bowel Syndrome

Target Audience

This activity is intended for gastroenterologists, primary care/family physicians, advanced practice providers and other members of the multidisciplinary team who manage patients with short bowel syndrome.

Overview

This Clinical Case Challenge is designed to actively engage learners in realistic, patient-centered scenarios that promote critical thinking, clinical reasoning and decision-making skills.

Educational Objectives

Upon completion of this activity, participants should be able to:

• Explain the clinical consequences and pathophysiology of short bowel syndrome and how they inform diagnosis and treatment planning.
• Identify evidence-based, multidisciplinary management strategies that address nutritional, fluid, and supportive care needs while addressing patient quality of life and functional goals.
• Evaluate the role and timing of pharmacologic therapies, including GLP-2 receptor agonists, in optimizing patient outcomes..

Faculty

John K. DiBaise, MD, FACG, FASPEN
Professor of Medicine, Division of Gastroenterology & Hepatology
Mayo Clinic Scottsdale

Financial Support

This activity is supported by an independent educational grant from Takeda Pharmaceutical Co.

Providers

Jointly provided by Partners for Advancing Clinical Education (Partners) and Novus Medical Education.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners and Novus Medical Education. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation for Physicians

Partners designates this enduring material for a maximum of 0.5  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr. DiBaise:
Advisor/consultant: Takeda Pharmaceuticals, Immunic Therapeutics, Lilly Pharmaceuticals
Research support: Zealand Pharmaceuticals, NorthSea Therapeutics

The directors, planners, managers and reviewers of this activity, both for Partners and Novus, have no relevant financial relationship(s) to disclose with ineligible companies.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Method of Participation

There are no fees for participating and receiving CME credit for this activity. To claim credit, participants must complete the following:

1. Review the target audience, accreditation information, learning objectives and faculty disclosures
2. View and digest the educational content in its entirety.
3. Complete the activity evaluation.
4. Physicians who complete the Case Challenge and complete the evaluation will receive a CME Statement of Credit.
5. All other participants who complete the Case Challenge and the evaluation will receive a Certificate of Participation.

We encourage you to complete the Activity Evaluation to provide feedback for future programming. After submitting the evaluation, you may download the certificate immediately from the confirmation page or afterward by clicking the Download Certificate button in your confirmation email. Records of all CME/CE activities completed can be found on the "My CMEstream" page.    

CME Provider

For additional information about the accreditation of this activity, please contact Partners at contactus@partnersed.com

System Requirements

This site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended. We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Firefox, Chrome, Safari or Edge.